Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)

What Was Tested

The paper reports a study of Angiotensin II, published as a randomized controlled trial.

To determine the effect of angiotensin-converting enzyme (ACE) inhibition on brachial flow-mediated vasodilation.

High resolution ultrasound was used to assess endothelium-dependent brachial artery flow-mediated vasodilation (FMD) in patients with coronary disease.

Who Took Part

According to the abstract, 80 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Each patient received three drugs with a two-week washout period between treatments.

How the Study Was Run

The design is described as randomized and crossover.

The patients were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

The methods mention a period of eight weeks.

The primary end point was the absolute difference in FMD after eight weeks of each study drug compared with their respective baselines analyzed in a blinded fashion.

What Was Measured

The subject headings attached to it are Amlodipine, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Blood Flow Velocity, Calcium Channel Blockers, Coronary Circulation and Coronary Disease.

What This Means in Plain Language

The paper is a randomized and crossover study of Angiotensin II in 80 patients over eight weeks.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (Journal of the American College of Cardiology), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.